Asuragen to Collaborate with Illumina on Companion Diagnostics Development

Austin, Texas – Date: September 9, 2015Asuragen, Inc., a global molecular diagnostics company, announced today that it had entered into a collaboration agreement with Illumina, Inc. (NASDAQ:ILMN) that establishes a framework for the development and commercialization of sequencing-based companion diagnostics in partnership with biotech and pharmaceutical companies.

Asuragen will leverage its QuantideX® NGS product platform for development of customized companion diagnostics for its biotech and pharma partners on the Illumina MiSeqDx™ instrument. Asuragen’s recently launched QuantideX® Pan Cancer Kit* demonstrates its optimized NGS system that unifies pre-analytical DNA QC, sample quantification, multiplex PCR enrichment, dual-index barcoding, and library purification and quantification, using reagents provided in a single kit. In addition, it integrates Asuragen’s analytics and reporting suite, the QuantideX® Reporter, providing a straight forward sample-to-answer solution for Asuragen NGS panels.

“We are uniquely positioned to be a nimble and high quality companion diagnostic partner to biotech and pharma”, said Matt McManus, President and CEO of Asuragen. “Sequencing-based companion diagnostic projects benefit from our established QuantideX® NGS product platform, which allows for rapid and efficient development of a unique DNA and/or RNA panel of interest. The Quantidex™ NGS system is built under design control and manufactured in our cGMP facility, providing a high quality basis for regulated diagnostic product development.”

* For Research Purposes Only. Not for use in diagnostic procedures.

About Asuragen
Asuragen is a molecular diagnostics company driving better patient management in oncology and genetic disorders through best-in-class clinical testing solutions. The company uses a breadth of technologies and scientific talent to discover, develop and commercialize diagnostic products for clinical laboratories and for our Bio/Pharma partners. Asuragen’s development of innovative diagnostic products will help transform medicine by improving clinical outcomes and health economics. For more information, visit

Lynne Hohlfeld
SVP, Corporate Development and Chief Financial Officer
Asuragen, Inc.


Back To